Welcome to our dedicated page for Silo Pharma news (Ticker: SILO), a resource for investors and traders seeking the latest updates and insights on Silo Pharma stock.
Silo Pharma Inc. (SILO) is a biopharmaceutical innovator developing novel therapies that combine traditional treatments with psychedelic research for conditions including PTSD and chronic pain. This dedicated news hub provides investors and researchers with essential updates on the company's clinical progress, strategic partnerships, and therapeutic advancements.
Access centralized, reliable information about Silo Pharma's pipeline developments, including its intranasal SPC-15 formulation for stress disorders and SP-26 implant technology for pain management. The page aggregates official press releases, research milestones, and financial disclosures while maintaining strict compliance with financial reporting standards.
Key updates cover clinical trial phases, intellectual property developments, university research collaborations, and regulatory filings. All content is verified through primary sources to ensure accuracy and timeliness for stakeholders tracking the company's progress in psychedelic-assisted therapeutics and advanced drug delivery systems.
Bookmark this page for streamlined access to Silo Pharma's latest announcements. For comprehensive tracking of the company's innovative approach to CNS disorder treatments, consider subscribing to Stock Titan's news alerts.
Silo Pharma (OTCQB: SILO) has entered into a Scientific Research Agreement with the University of Maryland, Baltimore, to investigate the efficacy of a novel peptide, ART-1, for delivering dexamethasone to treat rheumatoid arthritis. This study will utilize peptide-guided liposomes to potentially enhance the drug's efficacy and reduce toxicity. CEO Eric Weisblum emphasized the importance of this milestone for accessing a significant market and improving therapeutic targeting. The company aims to develop a technology platform adaptable for other drugs, enhancing treatment options for various conditions.
Silo Pharma has extended its exclusive option agreement with the University of Maryland, Baltimore to investigate novel joint-homing peptides aimed at treating rheumatoid arthritis. This extension allows Silo more time to evaluate a potentially transformative therapeutic platform that could enhance drug delivery for traditional and psychedelic treatments, which may improve efficacy while reducing toxicity. CEO Eric Weisblum emphasized the significance of this technology for targeted therapy delivery.
Silo Pharma, Inc. (OTCQB: SILO) has entered a Scientific Research Agreement with the University of California San Francisco (UCSF) to explore the effects of psilocybin on inflammatory markers in patients with Parkinson's, Bipolar disorder, and chronic back pain. This agreement will utilize four other planned clinical trials by UCSF. CEO Eric Weisblum emphasized the potential of psilocybin to reduce inflammation related to these conditions, which may improve treatment outcomes. The study will be conducted at UCSF's Translational Psychedelic Research Program, focusing on the impact of psychedelics on various disorders.
Silo Pharma, Inc. (OTCQB: SILO) announced the submission of its initial application to list on the NASDAQ Capital Market. This follows the board's prior approval to commence the up-listing process. The NASDAQ listing is contingent upon meeting regulatory requirements and acceptance by NASDAQ, which cannot be assured. CEO Eric Weisblum emphasized that a NASDAQ listing aims to enhance investor liquidity, attract institutional investors, and improve the company's visibility. Silo Pharma focuses on developing psychedelic therapies for conditions like depression and PTSD.
Silo Pharma, Inc. (OTCQB: SILO) announced the submission of its investigator-led study using Psilocybin for treating Parkinson’s disease for ethics board review in the Netherlands. CEO Eric Weisblum expressed satisfaction with this milestone and anticipates sharing more details with the scientific community and shareholders.
Silo Pharma is focused on merging traditional therapeutics with psychedelic research to assist patients suffering from conditions like depression, PTSD, and rare neurological disorders.
Silo Pharma (OTCQB: SILO) has announced a joint venture with Zylo Therapeutics to develop a sustained-release topical delivery system for ketamine and psilocybin. This collaboration aims to address the needs of patients with dysphagia, particularly those dealing with Alzheimer’s and Parkinson’s diseases. The ZTI’s Z-pod technology will enable the controlled delivery of these psychedelics, potentially reducing hallucinogenic effects while exploring their safety and efficacy. This initiative aligns with Silo Pharma's mission to innovate therapeutic solutions.
Silo Pharma, Inc. (OTCQB: SILO) announced its Board of Directors' unanimous decision to uplist to the NASDAQ. CEO Eric Weisblum emphasized that this move aims to enhance visibility and attract institutional investors, fostering long-term shareholder value. The uplisting is contingent upon meeting NASDAQ's listing requirements and securing approval. Silo Pharma focuses on developing psilocybin-based therapeutics for mental health issues and neurological disorders.
Silo Pharma, Inc. (OTCQB: SILO), a biopharmaceutical company focusing on psilocybin therapy, has finalized a sublicense agreement related to its provisional patent for CNS homing peptides aimed at treating pain from neuroinflammation in cancer patients. CEO Eric Weisblum expressed enthusiasm for the collaboration and emphasized the company's commitment to creating shareholder value while developing innovative therapeutics. The news comes on the heels of an earlier Letter of Intent from February, highlighting Silo's strategic growth.
Silo Pharma has entered an exclusive option agreement with the University of Maryland to investigate novel joint-homing peptides aimed at treating inflammation related to autoimmune diseases, specifically rheumatoid arthritis. These peptides could enhance drug delivery directly to affected joints, potentially increasing therapeutic efficacy while minimizing systemic toxicity. Silo's CEO emphasized the potential of this technology as a revolutionary drug delivery platform that meets the need for innovative treatments for patients with rare diseases.
Silo Pharma, a biopharmaceutical company, announced that CEO Eric Weisblum will present at Proactive's One2One Virtual Investor Forum on February 23, 2021, at 1 p.m. EST. The event is expected to reach Proactive's 20,000 YouTube subscribers and will be broadcasted globally. Silo Pharma focuses on merging traditional therapeutics with psychedelic research to address conditions such as depression, PTSD, and Parkinson's disease. The presentation will include a Q&A session and will be made available online after the event.
FAQ
What is the current stock price of Silo Pharma (SILO)?
What is the market cap of Silo Pharma (SILO)?
